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a b s t r a c t
Introduction: The ESC Heart Failure Long-Term Registry (ESC-HFLTR) is a prospective obser-
vational study which takes place in 211 cardiology centres of 21 European and Mediterra-
nean countries, members of the European Society of Cardiology.
Aim: To compare basic demographic and clinical characteristics of both, the patients
hospitalized for acute heart failure and the patients observed in outpatient clinics for
chronic heart failure in the Czech Republic with published European-wide data.
Methods: Altogether 692 consecutive patients were included in the Czech part of ESC-HFLTR
(5.6% of the whole registry) from May 2011 to April 2013. These patients were either admitted
to hospital or examined in the outpatient clinic for HF during one predeﬁned day of the week.
The basic characteristics of 160 hospitalized (25.3%) and 532 ambulatory (74.7%) patients
were analysed statistically, compared with each other and ﬁnally contrasted with available
data from the whole ESC-HFLTR.
Results: Czech in-hospital patients were generally older than the ambulatory patients with
HF (73 vs. 66 years; p < 0.001) and were less frequently men (62.5 vs. 75.7%). They had also
signiﬁcantly higher incidence of comorbidities. On the contrary, the outpatients underwent
more often pacemaker implantation and coronary revascularization than hospitalized
patients. The dominant HF aetiology was ischaemic in both groups. The HF with preserved
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ejection fraction was more frequently represented among the hospitalized HF patients. On
the other hand, more ambulatory patients had dilated cardiomyopathy as the primary cause
of HF.
In comparison with the data from the whole ESC-HFLTR Czech HF patients in both groups
had signiﬁcantly higher body weight, systolic blood pressure and higher incidence of
comorbidities. In addition, they had more frequently implanted a pacemaker.
Conclusion: Czech HF patients had worse cardiovascular risk proﬁle as well as higher inci-
dence of comorbidities compared to the patients from the whole ESC-HFLTR.
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. heTIntroduction
Prevalence of chronic heart failure (HF) in general population is
about 1–2%. However, it substantially rises above the age of 75
when it reaches over 8% and is one of the most frequent causes
of morbidity and mortality in this population [1]. Every year,
approximately 40,000 new cases of HF are diagnosed in the
Czech Republic [2]. Randomized clinical trials provide rela-
tively detailed information about basic characteristics of
speciﬁc HF patient groups. Nevertheless, these patient groups
are often highly selected. For the proper interpretation of
clinical study results there is a need of more information on
the whole HF population, from which these patients were
chosen. International epidemiological studies brought further
evidence to this topic [3–5] but these trials concerned rather for
prognosis, therapy and adherence to current guidelines than
for clinical characteristics of both, hospitalized and ambula-
tory HF patients. Moreover, there is a lack of national data,
which would describe the Czech population of HF patients and
how they differ compared to the European one.
The European Heart Failure Long-Term Registry (ESC-
HFLTR) gathered information from 21 European and Mediter-
ranean countries to observe how the European Society of
Cardiology (ESC) recommendations regarding pharmacologi-
cal as well as non-pharmacological treatment of HF are
adopted to clinical practice [3]. With the aim to obtain national
comparative data on basic demographic and clinical char-
acteristics of patients either hospitalized for acute HF or
observed in outpatient clinics for chronic HF we analysed data
from the Czech part of the ESC-HFLTR and compared it
subsequently with the information from the whole registry.
Methods
Study design
The ESC-HFLTR is a prospective multicentre observational
study which gathers information on ambulatory as well as
hospitalized HF patients from 211 cardiology centres in 21
European and Mediterranean member countries of the
European Society of Cardiology. The patients were enrolled
into the registry during one day per week for 24 months. The
main goal of the international survey was to evaluate how HF
treatment guidelines are incorporated to clinical practice. TheCzech part of the ESC-HFLTR consisted of seven cardiology
centres from which six were university hospitals and one was
community hospital. Basic demographic and clinical data
acquired from the Czech part of the ESC-HFLTR were analysed
separately. At ﬁrst, comparison of the hospitalized and the
outpatient part of Czech cohort was made. At second, the data
on the Czech HF patients were contrasted with the published
data from the whole registry [3].
Study population
One predeﬁned day in the week during 2-year period all
patients with chronic HF seen by the cardiologists in the
outpatient clinics, as well as those admitted to hospital for
either acute, pre-existing, or new onset of HF with the need of
intravenous therapy were included into the study. The
consecutive patients were chosen according to clinical
judgement of attending physicians. No speciﬁc inclusion/
exclusion criteria existed with the exception of the patient's
age higher than 18 years. The whole survey was approved by
The Czech Society of Cardiology.
Statistical analysis
Continuous variables are presented as medians and inter-
quartile range (IQR). Comparisons between continuous vari-
ables were made using the Student unpaired t-test. Categorical
variables are expressed as percentage and compared by x2 test.
The value of p < 0.05 was considered to be signiﬁcant. All
calculations were performed using commercially available
statistical software (STATISTICA Cz 12, StatSoft, Czech
Republic).
Results
Czech hospitalized vs. ambulatory heart failure patients
From May 2011 to April 2013 altogether 692 patients were
enrolled into the study. Of them 160 (23.1%) were hospitalized
for acute HF, while 532 (76.9%) were examined for chronic HF in
the outpatient setting. The Czech in-hospital patients were
generally older than the ambulatory patients (73 vs. 66 years;
p < 0.001) and were less frequently men (62.5 vs. 75.7%;
p < 0.001). They also had signiﬁcantly higher incidence of
comorbidities such as atrial ﬁbrillation (52.6 vs. 41.9%;
c o r e t v a s a 5 7 ( 2 0 1 5 ) e 6 – e 1 1e8p = 0.018), renal insufﬁciency (42.5 vs. 29.2%; p < 0.001),
peripheral vascular disease (26.9 vs. 18.4%; p = 0.02) and history
of stroke/transient ischaemic attack (20.0 vs. 8.5%; p < 0.001)
(Table 1). On the contrary, more ambulatory than hospitalized
HF patients were treated for diabetes mellitus (65.4 vs. 53.8%;
p = 0.008). The incidence of hypertension was relatively high but
similar in both groups (72.0 vs. 68.6%;p = ns). The aetiology of HF
wasischaemic in a little bit more than half of the patients in both
groups (52.6 vs. 51.3%; p = ns). Mean left ventricular ejection
fraction (LVEF) did not signiﬁcantly differ in both groups (35.4 vs.Table 1 – Basic characteristics of Czech hospitalized and






Age (years), median (IQR) 73 (64–82) 66 (59–75) <0.001
>75 years (%) 44 24 <0.001
Men (%) 62.5 75.7 0.001
BMI (kg/m2), median (IQR) 29 (25–32) 29 (26–32) ns
Obesity (%) 41.3 42.6 ns
Blood pressure (mmHg)
- Systolic, median (IQR) 135 (118–155) 130 (117–140) <0.001
- Diastolic, median (IQR) 80 (70–90) 80 (70–87) ns
Heart rate (bpm), median
(IQR)
84 (70–98) 71 (65–80) <0.001
LVEF (%), median (IQR) 31 (25–45) 33 (25–40) ns




Symptomatic CAD (%) 43.2 44.5 ns
Revascularization (%) 30.7 42.3 0.008
- CABG 12.5 18.6 ns
- PCI 22.5 31.6 0.027
Atrial ﬁbrillation (%) 52.6 41.9 0.018
Diabetes mellitus (%) 53.8 65.4 0.008
Hypertension (%) 72.0 68.6 ns
Stroke/TIA (%) 20.0 8.5 <0.001
PAD (%) 26.9 18.4 0.020
Valve surgery (%) 6.3 7.5 ns
Pacemaker (%) 30.7 47.0 <0.001
- DD 15.8 4.9 0.004
- ICD 8.1 15.8 0.014
- CRT-P 2.5 2.1 ns




VTE (%) 5.6 5.3 ns
COPD (%) 21.9 14.7 0.030
Renal dysfunction (%) 42.5 29.2 <0.001
- Creatinine (mmol/l) 110 (90–150) 99 (82–119) <0.001
Hepatic insufﬁciency (%) 9.4 4.1 0.010
Malignant diseases (%) 7.6 3.4 0.025
Depression (%) 5.6 5.3 ns
Active smokers (%) 16.3 10.3 0.041
BMI, body mass index; HF, heart failure; CABG, coronary artery
bypass grafting; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; CRT-P, cardiac resynchronization
therapy-pacemaker; CRT-D, cardiac resynchronization therapy-
deﬁbrillator; DD, dual chamber; ICD, implantable cardioverter-
deﬁbrillator; IQR, interquartile range; LVEF, left ventricular ejection
fraction; PAD, peripheral artery disease; PCI, percutaneous cor-
onary intervention; TIA, transient ischaemic attack; VTE, venous
thromboembolism.34.3%;p = ns). However, the diagnosis of HF with preserved LVEF
was much more common among hospitalized patients (9.4 vs.
3.8%; p = 0.005), whereas dilated cardiomyopathy was more
frequent in ambulatory patients (20.6 vs. 35.7%;p < 0.001) (Fig. 1).
Almost 60% of the patients admitted for HF to hospital already
had a history of this diagnosis and moreover, 20.6% of them
underwent HF hospitalization before.
Czech vs. European heart failure patients
The patients from the Czech Republic constituted 5.6% of the
whole ESC- HFLTR population. In comparison with all
European HF patients both, the Czech in-hospital as well as
the ambulatory patients had comparable age and the same
gender distribution. Nevertheless, the Czech HF patients had
signiﬁcantly higher body mass index (29 vs. 28%; p ≤ 0.001, for
both) and systolic blood pressure by the admission or
outpatient examination (135 vs. 130 mmHg; p = 0.003, 130
vs. 120 mmHg respective; p < 0.001). Generally, the Czech
population with acute as well as chronic HF had larger
amount of comorbidities than the European one. Czech
patients were more frequently treated for atrial ﬁbrillation,
diabetes mellitus, renal insufﬁciency, peripheral vascular
disease and other illnesses ( Tables 2 and 3). Number of
patients with implanted permanent pacemakers was also
higher in the Czech ambulatory HF patients compared to the
European ones (47.0 vs. 42.0%; p = 0.028). On the other hand,
the European ambulatory patients suffered more often from
depression in comparison with the Czech patients (7.9 vs.
5.3%; p = 0.048).
Discussion
The ESC-HFLTR provided a large amount of data about patients
from 21 European and Mediterranean countries either admit-
ted to hospital for acute HF or examined for chronic HF in the
outpatient clinics [3]. Each of the two cohorts represents
relatively different group of patients with a great variety of
underlying pathophysiological mechanisms leading to HF and
many concomitant diagnoses. Moreover, available informa-
tion on basic clinical characteristics of Czech patient with
acute as well as chronic HF is quite rare and mainly derived
from clinical studies and registries focused dominantly on
therapy and prognosis [6,7]. Therefore, we analysed demo-
graphic and clinical data from the Czech part of the ESC-HFLTR
and compared the hospitalized acute HF patients with the
chronic HF outpatients in the ﬁrst place. As expected, we found
a lot of signiﬁcant differences between the two patient groups.
The hospitalized acute HF patients are older and have a higher
rate of different comorbidities than the ambulatory patients
with chronic HF. The Acute Heart Failure Database (AHEAD)
Main registry showed worsening in-hospital as well as long-
term prognosis of acute HF patients with increasing age and
increasing number of comorbidities [6,8]. Surprisingly, the
prevalence of several comorbidities in hospitalized patients,
such as diabetes mellitus, renal dysfunction and atrial
ﬁbrillation, was very high in the ESC-HFLTR and exceeded
their prevalence found in other databases of acute HF patients
[6,9].
Fig. 1 – Aetiology of heart failure in Czech hospitalized and ambulatory patients. CAD, coronary artery disease; DCM, dilated
cardiomyopathy; HFPEF, heart failure with preserved ejection fraction; TICM, tachycardia induced cardiomyopathy.
Table 3 – Basic characteristics of Czech and European
ambulatory patients with heart failure.
Czech European p
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HF in both groups of our patients. Nevertheless, HF with
preserved LVEF (>45%) was less frequently diagnosed in the
outpatient cohort (only 13%) although these patients have
relatively favourable prognosis [6]. The lack of speciﬁc
recommendations for treatment of HF-PEF and questionable
beneﬁt from intensiﬁed pharmacotherapy might contribute to
smaller interest in these patients in Czech cardiology clinics.
In the next step we focused on the comparison of Czech and
all European HF patients from the ESC-HFLTR. Maggioni et al.Table 2 – Basic characteristics of Czech and European






Age (years), median (IQR) 73 (64–82) 71 ns
>75 years (%) 44 39.5 ns
Men (%) 62.5 62.7 ns
BMI (kg/m2), median (IQR) 29 (25–32) 28 (25–31) 0.001
Blood pressure (mmHg)
- Systolic, median (IQR) 135 (118–155) 130 (110–150) 0.003
Heart rate (bpm), median
(IQR)
84 (70–98) 88 (73–104) ns
LVEF (%), median (IQR) 31 (25–45) 38 (30–51) ns




Ischaemic aetiology (%) 52.6 54.0 ns
Atrial ﬁbrillation (%) 52.6 44.0 0.033
Diabetes mellitus (%) 53.8 38.9 <0.001
Hypertension (%) 72.0 64.5 ns
Stroke/TIA (%) 20.0 13.0 0.01
PAD (%) 26.9 14.2 <0.001
COPD (%) 21.9 20.2 ns
Renal dysfunction (%) 42.5 26.4 <0.001
Hepatic insufﬁciency (%) 9.4 8.4 ns
Depression (%) 5.6 7.9 ns
BMI, body mass index; HF, heart failure; COPD, chronic obstructive
pulmonary disease; IQR, interquartile range; LVEF, left ventricular
ejection fraction; PAD, peripheral artery disease; TIA, transient
ischaemic attack.[9] proved signiﬁcant differences in basic characteristics as
well as clinical outcome of patients with acute and chronic HF
across European regions. The HF population from Eastern
European countries (Poland, Romania) had lower risk proﬁle(n = 532) (n = 7401)
Age (years), median (IQR) 66 (59–75) 66 (57–75) ns
>75 years (%) 24 26.0 ns
Men (%) 75.7 71.2 0.025
BMI (kg/m2), median (IQR) 29 (26–32) 28 (25–31) <0.001
Blood pressure (mmHg)
- Systolic, median (IQR) 130 (117–140) 120 (110–136) <0.001
Heart rate (bpm), median
(IQR)
71 (65–80) 70 (62–80) <0.001
LVEF (%), median (IQR) 33 (25–40) 35 (28–45) 0.002




Ischaemic aetiology (%) 51.3 43.0 <0.001
Atrial ﬁbrillation (%) 41.9 37.6 0.048
Diabetes mellitus (%) 65.4 31.8 <0.001
Hypertension (%) 68.6 58.2 <0.001
Stroke/TIA (%) 8.5 9.4 ns
PAD (%) 18.4 12.3 <0.001
COPD (%) 14.7 20.2 ns
Renal dysfunction (%) 29.2 26.4 <0.001
Hepatic insufﬁciency (%) 4.1 8.4 ns
Depression (%) 5.3 7.9 0.048
Pacemaker (%) 47.0 42.0 0.028
- DD 10.4 13.8 ns
- ICD 33.6 56.0 <0.001
- CRT 56.0 30.2 <0.001
BMI , body mass index; HF, heart failure; COPD, chronic obstruc-
tive pulmonary disease; CRT, cardiac resynchronization
therapy; DD, dual chamber; ICD, implantable cardioverter-
deﬁbrillator; IQR, interquartile range; LVEF, left ventricular
ejection fraction; PAD, peripheral artery disease; TIA, transient
ischaemic attack.
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European regions. Unfortunately, the Czech Republic did not
participate in this survey. Within the frame of the ESC-HFLTR
the Czech Republic was also counted among Eastern European
countries [3]. Nevertheless, Czech acute as well as chronic HF
patients presented worse cardiovascular risk proﬁle having
signiﬁcantly higher incidence of obesity, diabetes mellitus and
hypertension compared to the patients from the whole registry.
We attribute this ﬁnding to healthier lifestyle of Mediterranean
population which formed substantial part of the ESC-HFLTR.
Higher rate of pacemaker implantation among Czech ambula-
tory HF patients could be related to different economic situation
across European and Mediterranean regions.
Hradec et al. [7] analysed clinical characteristics and
pharmacotherapy of the Czech patients with chronic ischae-
mic HF using subanalysis of CORONA study. Similarly to our
results, the authors described higher occurrence of hyperten-
sion, diabetes mellitus and atrial ﬁbrillation in the Czech
cohort compared to the whole CORONA study population.
Interestingly, worse cardiovascular risk proﬁle of the Czech
patients did not result in worse prognosis. However, this
analysis was limited only to patients with systolic HF of
ischaemic aetiology [7].
We also conﬁrmed signiﬁcantly higher number of coronary
revascularizations among the Czech patients with chronic HF
compared to all European HF patients. Over half of the Czech
HF patients with proved coronary artery disease underwent
either percutaneous coronary intervention (31.6%) or coronary
artery bypass grafting (18.6%). These numbers are even higher
than in the Czech subpopulation of the CORONA study
(revascularization in 31%) [7]; however, this trial took place
more than 10 years ago.
Limitations
Our study had several limitations which have to be acknowl-
edged. In agreement with the protocol of the ESC-HFLTR the
diagnosis of HF was made by the investigators according to
their clinical judgement only and not validated centrally.
Moreover, no speciﬁc inclusion criteria, such as natriuretic
peptides level or echocardiography ﬁnding had to be fulﬁlled to
enrol a patient. To decrease the investigators workload
patients were recruited on one day per week basis. Therefore,
consecutiveness of patient enrolment cannot be guaranteed.
The representativeness of analysed population is commonly
discussed in observational studies. Unfortunately, only one of
the seven participating cardiology centres in the Czech Republic
was situated in regional hospital. Accordingly, the selected HF
patient group may not represent the whole population of HF
patients. Furthermore, the total of hospitalized HF patients was
relatively low and could weaken statistical analysis. Finally, the
Czech cohort formed a part of the whole ESC-HFLTR which
means that the real differences between Czech and European HF
patients could be even more pronounced.
Conclusions
The Czech population from the ESC-HFLTR admitted to
hospital for acute HF or observed in the outpatient settingfor chronic HF represent two separate groups of patients. The
in-hospital patients are older, more frequently females and
have more comorbidities in comparison with the ambulatory
patients. Half of the patients with chronic HF who are followed
up in Czech cardiology clinics underwent coronary revascu-
larization and almost half also pacemaker implantation. The
HF-PEF is relatively rare diagnosis among the ambulatory
patients.
Our ﬁndings support the idea of regional differences in HF
populations across Europe. In contrast with the patients from
the whole ESC-HFLTR, Czech HF patients had worse cardio-
vascular risk proﬁle as well as higher prevalence of comorbid-
ities. Moreover, Czech ambulatory patients had more
frequently implanted a pacemaker than the European ones.
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